Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.58 |
| ▸ | ALPL | P05186 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL970232 | 0.84 | ALPL (0.57) | HPGDSALPLMAPTRAB9ANPC1 | |
| SCHEMBL1007015 | 0.82 | MAPK1 (0.61) | HPGDSALPLMAPTRAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL28348020 | 0.82 | ALPL (0.56) | HPGDSALPLMAPTRAB9ANPC1 | |
| SCHEMBL1430763 | 0.81 | ALPL (0.55) | HPGDSALPLMAPTRAB9ANPC1 | |
| SCHEMBL17593138 | 0.81 | ALPL (0.55) | HPGDSALPLMAPTRAB9ANPC1 | |
| SCHEMBL23212271 | 0.81 | ALPL (0.55) | HPGDSALPLMAPTRAB9ANPC1 | |
| SCHEMBL16763424 | 0.81 | ALPL (0.55) | HPGDSALPLMAPTRAB9ANPC1 | |
| SCHEMBL1403922 | 0.81 | ALPL (0.55) | HPGDSALPLMAPTRAB9ANPC1 | |
| SCHEMBL4311802 | 0.81 | ALPL (0.55) | HPGDSALPLMAPTRAB9ANPC1 | |
| Ethane SCHEMBL6614658 | 0.81 | MAPK1 (0.59) | HPGDSALPLMAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101971-A2 | EGFR INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260070924-A1 | INDAZOLE MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4705308-A1 | EGFR INHIBITORS FOR TREATING DISEASE | Blossomhill Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4562015-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-12319703-B2 | Macrocyclic fused pyrazoles as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-06-03 | — | — | US | disclosed |
| EP-4536224-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | Blossomhill Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536225-A1 | INDAZOLE MACROCYCLES AND THEIR USE | Blossomhill Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025049419-A1 | PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS | GENZYME CORPORATION (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-119431365-A | Phenyl heterocyclic derivative-containing regulator and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20080306056-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| US-7429581-B2 | Pyrazole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-09-30 | — | — | US | disclosed |
| US-20080221329-A1 | Novel and economical process for preparing (S, S)-2, 8-diazabicyclo[4.3.0]nonane and its enantiomer | LIANYUNGANG JINKANG PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) | 2008-09-11 | — | — | US | disclosed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
| EP-1581523-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| US-20040204406-A1 | Pyrazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-14 | — | — | US | disclosed |
| WO-2004056815-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306056-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | F12, F5, F11 | HPGDS 1027/4885ALPL 2581/4885MAPT 4744/4885 |
| US-20260070924-A1 | INDAZOLE MACROCYCLES AND THEIR USE | NR0B2, NR0B1, ESRRA | HPGDS 3190/4885ALPL 3097/4885MAPT 3932/4885 |
| US-20080221329-A1 | Novel and economical process for preparing (S, S)-2, 8-diazabicyclo[4.3.0]nonane and its enantiomer | SULT1E1, CYP4X1, SULT1A1 | HPGDS 1708/4885ALPL 2077/4885MAPT 4747/4885 |
| US-20040204406-A1 | Pyrazole-derivatives as factor Xa inhibitors | F11, F5, F12 | HPGDS 1509/4885ALPL 2984/4885MAPT 4830/4885 |
| US-12319703-B2 | Macrocyclic fused pyrazoles as Mcl-1 inhibitors | MCL1, BCL2A1, BCL2L1 | HPGDS 2904/4885ALPL 4530/4885MAPT 2417/4885 |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | KDR, MUSK, FLT4 | HPGDS 2141/4885ALPL 4285/4885MAPT 3744/4885 |
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | AADAC, PAICS, CYP3A43 | HPGDS 865/4885ALPL 3735/4885MAPT 1517/4885 |
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | HPGDS 4430/4885ALPL 4260/4885MAPT 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.